Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -98.62% | -98.52% | -92.33% | -87.00% | -34.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.62% | -98.52% | -92.33% | -87.00% | -34.71% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -98.62% | -98.52% | -92.33% | -87.00% | -34.71% |
| SG&A Expenses | 11.83% | 13.01% | 2.25% | -6.48% | -16.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.61% | 35.65% | 29.80% | 20.24% | 10.44% |
| Operating Income | -109.06% | -193.21% | -203.16% | -214.36% | -90.32% |
| Income Before Tax | -113.88% | -196.60% | -205.39% | -222.31% | -100.08% |
| Income Tax Expenses | 218.86% | -199.39% | -128.35% | -114.36% | -114.36% |
| Earnings from Continuing Operations | -114.48% | -191.34% | -197.15% | -213.90% | -94.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 62.98% | 155.00% | 182.00% | 250.89% | 557.14% |
| Net Income | -115.53% | -192.04% | -197.41% | -213.43% | -92.09% |
| EBIT | -109.06% | -193.21% | -203.16% | -214.36% | -90.32% |
| EBITDA | -112.51% | -202.58% | -213.09% | -226.81% | -94.40% |
| EPS Basic | -86.16% | -160.56% | -173.05% | -197.91% | -89.69% |
| Normalized Basic EPS | -86.20% | -166.00% | -181.06% | -205.74% | -93.14% |
| EPS Diluted | -85.99% | -160.32% | -172.72% | -197.07% | -88.91% |
| Normalized Diluted EPS | -85.80% | -165.16% | -180.05% | -204.43% | -92.29% |
| Average Basic Shares Outstanding | 15.94% | 12.24% | 8.56% | 4.83% | 1.22% |
| Average Diluted Shares Outstanding | 15.57% | 11.87% | 8.20% | 4.48% | 0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
